Daridorexant at Midlife: What the Menopause-Age Subgroup Shows

A study of women in their late forties and early fifties can inform a sleep consultation. Before applying its findings to menopause-related insomnia, check how the women were selected and how precise the results were.

Was this a trial specifically enrolling women with menopause-related insomnia?

The 2026 report analyzed 117 women aged 47–55 from a three-month insomnia trial: 35 on 50 mg, 43 on 25 mg and 39 on placebo. Selection was by age, rather than menopause-related insomnia.¹

What did 50 mg change compared with placebo?

Adjusted month-three estimates, with 95% confidence intervals, were:¹

• Laboratory-measured waking after sleep onset: 13.8 fewer minutes (29.0 fewer to 1.4 more).
• Laboratory-measured time to persistent sleep: 14.7 fewer minutes (30.0 fewer to 0.6 more).
• Diary-reported sleep: 21.8 more minutes (3.9 fewer to 47.4 more).
• Total daytime symptom/impact score: 4.1 points lower (14.4 lower to 6.3 higher).

Every interval includes zero difference. These estimates favor treatment but remain compatible with no benefit; they do not prove no benefit. Three authors were Idorsia employees.¹

What is the dedicated menopause study testing?

CELESTE compares digital cognitive behavioral therapy for insomnia, trazodone and daridorexant, with treatment or program access over 12 months. Its primary outcome is a patient-reported sleep-disturbance score at six months.²

The registry update posted June 8, 2026, checked October 16, lists recruiting, 1,000 planned participants and no posted results. Eligibility includes ages 40–62, peri- or early menopause, and insomnia that started or worsened during that transition, alongside further screening requirements. This study cannot yet tell a reader which option performed best.²

Does the subgroup remove next-morning precautions?

The US QUVIVIQ label covers adult insomnia involving difficulty falling or staying asleep. It requires at least seven hours before planned awakening and warns about next-day impairment, including driving. Alcohol adds impairment risk; narcolepsy is a contraindication. If complex sleep behavior such as sleepwalking occurs, the label calls for immediate discontinuation.³

Our daridorexant driving-study explanation examines that separate evidence. Feeling less sleepy and having unimpaired driving performance are different outcomes.

What should I bring to the appointment?

Write down whether your main difficulty is falling asleep, repeated waking or functioning the next day. Bring your medicine list and a practical treatment goal, such as staying awake through the morning commute without struggling.

“Medicines Belong in Shared Decisions” in Did I Do That in My Sleep? frames the discussion around expected benefit, adverse effects, interactions, next-day impairment, cost and a review plan. Ask which evidence applies to your situation and when you will reassess the chosen treatment.